Ex Vivo Organotypic Brain Slice Models for Glioblastoma: A Systematic Review
Cancers · 25.01.2026 · 18 (3) · 372
DOI: 10.3390/cancers18030372 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.01.2026. Verfasst von Cateno C T Petralia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Policlinico "G. Rodolico-San Marco" University Hospital, 95123 Catania, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objective: This systematic review aims to evaluate ex vivo brain slice models in glioblastoma (GBM) research, with a specific focus on tumour invasion, tumour–microenvironment interactions, and therapeutic response.
Methods
A systematic search looking for studies employing ex vivo organotypic brain slice models in GBM research was conducted across multiple databases (January 2010–July 2025) in accordance with PRISMA guidelines. The study was registered in PROSPERO database (CRD420251138341). Inclusion criteria encompassed patient-derived brain slices, hybrid rodent–human slice co-cultures, and microfluidic-integrated ex vivo platforms designed to assess tumour invasion, microenvironmental interactions and therapeutic responses. Exclusion criteria included reviews, abstracts, conference proceedings, in vivo-only studies, purely in vitro models without organotypic integration, and studies not focused on GBM.
Results
Twenty-six studies met the inclusion criteria. Among these, 18/26 (69%) investigated GBM invasion, 18/26 (69%) evaluated therapeutic responses, and 5/26 (19%) examined tumour–microenvironment interactions, with several studies spanning multiple domains. Across platforms, organotypic slices consistently recapitulated key features of GBM biology—including perivascular and white-matter-aligned invasion, stromal–immune interactions, and patient-specific drug sensitivity—while engineered systems enhanced perfusion and exposure control. Methodological variability, particularly regarding slice preparation, oxygenation and viability assessment, limits direct comparability between studies.
Conclusions
Organotypic brain slice models represent an extremely relevant tool for translational investigations of GBM biology and treatment response. However, substantial methodological heterogeneity together with limited standardisation hamper reproducibility and cross-study validation. Future work should focus on enhancing reproducibility and harmonising protocols to support the development of clinically meaningful precision oncology strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Policlinico "G. Rodolico-San Marco" University Hospital, 95123 Catania, Italy.
- Department of Drug and Health Sciences, University of Catania, 95124 Catania, Italy.
- Section of Anatomy, Histology and Movement Sciences, Department of Biomedical and Biotechnological Sciences, University of Catania, 95124 Catania, Italy.
- Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia" Anatomic Pathology, University of Catania, 95124 Catania, Italy.
ORCID-Profile: Cateno C T Petralia, Velia D'Agata, Giuseppe Broggi
Zitieren
APA
Petralia, C. C. T., D'amico, A. G., D'Agata, V., Broggi, G., & Barbagallo, G. M. V. (2026). Ex Vivo Organotypic Brain Slice Models for Glioblastoma: A Systematic Review. Cancers, 18(3), 372. https://doi.org/10.3390/cancers18030372
Vancouver
Petralia CCT, D'amico AG, D'Agata V, Broggi G, Barbagallo GMV. Ex Vivo Organotypic Brain Slice Models for Glioblastoma: A Systematic Review. Cancers. 2026;18(3):372. doi:10.3390/cancers18030372
BibTeX
@article{Petralia2026,
author = {Petralia, Cateno C T and D'amico, Agata G and D'Agata, Velia and Broggi, Giuseppe and Barbagallo, Giuseppe M V},
title = {Ex Vivo Organotypic Brain Slice Models for Glioblastoma: A Systematic Review},
journal = {Cancers},
year = {2026},
volume = {18},
number = {3},
pages = {372},
doi = {10.3390/cancers18030372}
}
EUVIMED